The Icos Alumni: Where Are They Now?

11/18/09Follow @xconomy

(Page 4 of 9)

Kerry Fowler, principal, KFW Consulting

Paul Fredlund, biotechnology consultant

Steven Frey, Theraclone Sciences

Mark Fromhold, vice president of manufacturing and process development, Koronis Pharmaceuticals

Lyn Frumkin, biotechnology consultant

Michael Gallatin, president, Calistoga Pharmaceuticals

Christopher Gann, vice president, Starbucks

Bob Garcia Jr., senior research associate scientist, Genentech

Leon Garcia-Martinez, associate director, Alder Biopharmaceuticals

Jeff Gardin, IT director, CMC Icos

Dean Gittleman, senior director of biometrics, Vertex Pharmaceuticals [Added 12/30/09]

Phyllis Goldman, senior program manager, Merck

David Goodkin, independent biotechnology professional

Kathy Goodman, executive assistant

Rebecca Gottschalk, senior research associate, Trubion Pharmaceuticals

Patrick Gray, chief scientific director, Accelerator

Melanie Gray, medical student

Jacinthe Guindon, director of clinical operations, Viventia Biotech

Stephen Hadley, vice president of quality, CMC Icos

Jim Halbrook, senior research scientist, Albany Molecular Research

Kristi Hamilton, research associate III, Institute for Systems Biology

Christine Hansen, senior research associate, Seattle Genetics

Lori Hansen, director of project management, Seattle Genetics

Kevin Harbol, senior group leader, Omeros

Pat Hardwick, information technology support manager, College Success Foundation

Justin Hare, in vivo toxicology study coordinator, Amgen

Edith Harris, scientist, Mirina

Nataly Hawthorn, biotechnology professional

Joel Hayflick, former senior oncology early product development team leader, Genentech

Allen Heck, director of operations, Northshore Sheet Metal

Lee Hendrickson, owner, Side Street Photographics

Christopher Henney, chairman of the board, Oncothyreon, director, AVI Biopharma

Kelly Hensley, senior associate scientist, Amgen … Next Page »

Single Page Currently on Page: 1 2 3 4 5 6 7 8 9 previous page

By posting a comment, you agree to our terms and conditions.

  • http://www.northcoastbio.com Johnny T. Stine

    I actually loved our logo – very simple, but it just looked like fun.
    When George R. was recently asked by a reporter from an Everett newspaper about building Icos into a company like Amgen….he replied “…..why would I stop there?”. With a leader like that, like George, one who inspires with energetic goals such as that mentioned – we could’ve done it. We had the tools and the ability to do just that. We had great people who’ve all proven themselves in places before and afterward…….but imagine what we could’ve done behind the hopes of a great leader like George who set that tone….a CEO who knew all of our names, someone who would talk to you like you were a valued asset, a guy that empowered us via ownership. Imagine what we could’ve done…..because that’s all we’re left to do.

    By the way- Luke – I prefer Icosanoids – a play on the word eicosanoid since we were primarily an inflammation company. :-)

  • http://www.xconomy.com/author/ltimmerman/ Luke Timmerman

    Johnny—Unfortunately, I never really got to know George very well because he had already left Icos by the time I started covering the company in 2001. But I made a point of meeting him at his home once a couple years ago when I was based in San Francisco. He wasn’t in great health, but he was still sharp and very much curious about the latest happenings in biotech.

    I haven’t heard the term Icosanoids from eicosanoid, but that made me laugh this morning. It sounds like something from Star Trek. Anybody know if this was also the inspiration for the term “Immunoids” for people who used to work at Immunex?

  • http://www.BiotechStockResearch.com David Miller

    Nice work, Luke. Goes to prove that even though we might lose companies through acquisition we’d really rather keep, it’s not like everything connected with the company disappears. By my eye, the “loss” of Icos created at least a half-dozen new companies and significantly strengthened a dozen or more startups. A nice silver lining.

  • Abby Kliphardt

    Nice article…good to see where my co-workers have ended. I loved my time at ICOS and will always lament the loss of a great company that was a real family….

  • Pingback: The Icos Impact: What to Expect Next Week | Xconomy